Clinical Trials Sponsored by Alder Biopharmaceuticals, Inc.

Total 122 results

Alder Biopharmaceuticals, Inc.

Completed

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PROMISE 2)

Migraine Disorders

United States, Belgium, Italy, Spain, United Kingdom, Germany, Hungary, Georgia, Slovakia, Russian Federation, Ukraine, Denmark, Czechia
Alder Biopharmaceuticals, Inc.

Completed

A Multicenter Assessment of ALD403 in Chronic Migraine

Migraine Disorders

United States, Georgia, Australia, New Zealand
Alder Biopharmaceuticals, Inc.

Completed

Safety Tolerability and Pharmacokinetics of ALD403

Migraine Disorders

Australia
Alder Biopharmaceuticals, Inc.

Completed

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine (PREVAIL)

Migraine Disorder

United States
Alder Biopharmaceuticals, Inc.

Completed

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine (PROMISE 1)

Migraine Disorders

United States, Georgia
Alder Biopharmaceuticals, Inc.

Completed

Safety, Efficacy and Pharmacokinetics of ALD403

Migraine

United States
H. Lundbeck A/S
Alder Biopharmaceuticals, Inc.

Completed

Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman

Migraine

Australia
H. Lundbeck A/S
Alder Biopharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine (RELIEF)

Migraine

United States, Georgia
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Impaired Hepatic Function

United States
NGM Biopharmaceuticals, Inc

Completed

Study of NGM395 in Adult Participants

Obesity | NAFLD

Australia
NGM Biopharmaceuticals, Inc

Completed

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

Cachexia

Australia
NGM Biopharmaceuticals, Inc

Completed

Study of NGM313 in Obese Participants

Obese

United States
NGM Biopharmaceuticals, Inc

Completed

Phase 1 Study of NGM313 in Healthy Adult Participants

Obesity

Australia
RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

Myocardial Infarction | Myocardial Ischemia

United States
AgoneX Biopharmaceuticals, Inc.

Not yet recruiting

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis

Migraine Prophylaxis
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Nonalcoholic Steatohepatitis | Compensated Cirrhosis

United States, Australia, Belgium, France, Germany, Hong Kong, Poland, Puerto Rico, United Kingdom
NGM Biopharmaceuticals, Inc

Active, not recruiting

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Melanoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Metastatic Castration-resistant Prostate Cancer | Head Neck Squamous Cell Carcinoma

United States
NGM Biopharmaceuticals, Inc

Terminated

A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

SARS-CoV-2 Infection

Australia
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

Healthy Male

United States
NGM Biopharmaceuticals, Inc

Completed

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
NGM Biopharmaceuticals, Inc

Completed

Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis

United States, France, Netherlands, United Kingdom
NGM Biopharmaceuticals, Inc

Completed

Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals

Functional Constipation

United States
RegeneRx Biopharmaceuticals, Inc.

Terminated

A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Epidermolysis Bullosa
Gracell Biopharmaceuticals, Inc.

Recruiting

A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma

United States
NGM Biopharmaceuticals, Inc

Completed

A Study of NGM621 in Participants With Geographic Atrophy (CATALINA)

Geographic Atrophy

United States
RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction

ST Elevation Myocardial Infarction | Acute Myocardial Infarction | STEMI
NGM Biopharmaceuticals, Inc

Completed

Study of NGM621 in Participants With Geographic Atrophy

Geographic Atrophy

United States
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

Impaired Renal Function

United States
NGM Biopharmaceuticals, Inc

Completed

Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants

Diabetes Mellitus

Australia
RegeneRx Biopharmaceuticals, Inc.

Completed

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

Pressure Ulcers

United States
Paradigm Biopharmaceuticals USA (INC)

Active, not recruiting

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Osteoarthritis, Knee

Australia, United States
Paradigm Biopharmaceuticals USA (INC)

Active, not recruiting

An Observational Follow-up Study to Evaluate Duration of Treatment Effect of Pentosan Polysulfate Sodium in Participants With Knee Osteoarthritis Pain

Osteoarthritis, Knee

United States, Australia
Asklepios Biopharmaceutical, Inc.

Recruiting

NAN-101 in Patients With Class III Heart Failure (NAN-CS101)

Cardiovascular Diseases | Heart Failure | Heart Failure, Diastolic | Congestive Heart Failure | Heart Failure, Systolic | Heart Disease, Ischemic | Heart Failure，Congestive | Heart Arrhythmia | Heart; Complications

United States
Asklepios Biopharmaceutical, Inc.

Recruiting

Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

Parkinson's Disease | Multiple System Atrophy | Multiple System Atrophy, Parkinson Variant

United States, Poland
Asklepios Biopharmaceutical, Inc.

Recruiting

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure (GenePHIT)

Congestive Heart Failure

United States
Asklepios Biopharmaceutical, Inc.

Recruiting

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Muscular Dystrophy | Limb Girdle Muscular Dystrophy | LGMD2I | LGMD | Limb-Girdle Muscular Dystrophy Type 2 | LGMD2 | FKRP | FKRP Mutation | Fukutin Related Protein

United States
Asklepios Biopharmaceutical, Inc.

Active, not recruiting

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease

Pompe Disease

United States
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

CD20-positive B-cell Non-Hodgkin's Lymphoma

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors

Advanced Breast Cancer | Advanced Solid Tumor | Advanced Gastric Cancer

United States
Zhejiang Clover Biopharmaceuticals, Inc.

Active, not recruiting

Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China

COVID-19

China
Ethicon, Inc.
OMRIX Biopharmaceuticals

Completed

The Fibrin Patch Soft Tissue Study

Hemostasis

United States
Ethicon, Inc.
OMRIX Biopharmaceuticals

Completed

A Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Sutured Dural Repair

Dura Defects

Belgium, Finland, France, Germany, Netherlands, United Kingdom
Ethicon, Inc.
OMRIX Biopharmaceuticals

Completed

A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery

Cardiovascular, Neurologic (Spine), and General Surgery

United States
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Type 2 Diabetes

Diabetes Mellitus

Australia, New Zealand
Thomas A. Aller, OD
SynergEyes, Inc.

Withdrawn

Can Distance Center and Near Center Multifocal Contact Lenses Control Myopia Progression in Children? (ADPADP)

Myopia | Myopia, Progressive

United States
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumor | Classic Hodgkin Lymphoma

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Not yet recruiting

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

B-cell Non-Hodgkin's Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Not yet recruiting

IMM40H Phase I Dose Escalation and Expansion

Tumor
Sichuan Clover Biopharmaceuticals, Inc.

Recruiting

A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)

Chemotherapy-induced Thrombocytopenia (CIT)

China
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France

Clinical Trials Sponsored by Alder Biopharmaceuticals, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations